Data
-
New pulmonary embolism treatments offer patients freedom from needles
Treatments for pulmonary embolisms (PE) will evolve to better suit patient needs and enhance their quality of life, according to a report by GlobalData.
Data | 24 May 2012
-
Weak narcolepsy drug pipeline provides opportunities for pharma companies
The narcolepsy therapeutics developmental pipeline is weak, with only six molecules in development, providing opportunities for drugs companies to expand into this market, a study by healthcare intelligence specialist GlobalData has found.
Data | 07 March 2012
-
High resolution data
Agilent Technologies Inc introduced the SureScan Microarray Scanner, the latest innovation in scanner technology and the foundation of Agilent’s complete microarray solution for both gene expression and CGH/cytogenetics research applications.
Data | 27 January 2012
-
Drug Process Licensing Associates launches pharma database
PHILL, which stands for PHarmaceutical InteLLigence, is a database of bulk drug and intermediates producer information pertinent to members of the chemical and pharmaceutical industry. It also includes regulatory information such as Drug Master Files, Veterinary Master Files, Certificates of Suitability and Drug Approvals.
Data | 27 January 2012
-
Ziopharm Oncology presents preclinical data for Darinaparsin at AACR-NCI-EORTC meeting
Ziopharm Oncology announced that results from preclinical studies of darinaparsin (Zinapar or ZIO-101), a novel organic arsenic, in prostate cancer were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. In addition to company authors, the studies included authors Joseph R Bertino MD and Nitu Bansal PhD from UMDNJ-The Cancer Institute of New Jersey.
Data | 23 November 2011
-
Vorapaxar’s data presented at AHA, published in NEJM
Researchers presented and published results from TRACER (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome), the first clinical outcomes trial of vorapaxar, the investigational Protease Activated Receptor 1 (PAR-1) thrombin receptor antagonist from Merck (known as MSD outside the US and Canada).
Data | 18 November 2011
-
New data presented on phase 3 trial Of ELIQUIS (apixaban) in the prevention of venous thromboembolism in patients with acute medical illness
Bristol-Myers Squibb and Pfizer announced the results of the Phase 3 ADOPT (Apixaban Dosing to Optimize Protection from Thrombosis) trial, which evaluated apixaban versus enoxaparin in acutely ill medical patients, did not meet the primary efficacy outcome of superiority to enoxaparin for the endpoint of venous thromboembolism (VTE) and VTE-related death at day 30.
Data | 15 November 2011
-
Surge in investment in electronic data systems by pharma sector
Ovum predicts strong demand in Asia Pacific for EDC solutions as the region continues to host an ever increasing share of multinational clinical trials.
Data | 11 October 2011
-
Lilly announces review of data on long term raloxifene treatment
Eli Lilly and Company announced that data on EVISTA (raloxifene HCl tablets) therapy for more than three years was published online in Current Medical Research & Opinion. The review includes summaries of previously published information; new, previou…
Data | 10 August 2011
-
LSK Global PS joins Medidata Solutions channel partner program
Medidata Solutions announced that South Korean contract research organization (CRO) LSK Global PS has joined Medidata’s ASPire to Win channel partner program for CROs and other service providers. With this partnership, LSK becomes Medidata’s seco…
Data | 09 June 2011
